Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2011 1
2012 3
2013 2
2014 3
2015 2
2016 2
2017 2
2018 1
2019 4
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage.
Warren NJH, Eastman A. Warren NJH, et al. Oncogene. 2020 Feb;39(7):1389-1401. doi: 10.1038/s41388-019-1079-9. Epub 2019 Oct 28. Oncogene. 2020. PMID: 31659257 Free PMC article. Review.
A miRNA signature in endothelial cell-derived extracellular vesicles in tumor-bearing mice.
McCann JV, Liu A, Musante L, Erdbr├╝gger U, Lannigan J, Dudley AC. McCann JV, et al. Sci Rep. 2019 Nov 14;9(1):16743. doi: 10.1038/s41598-019-52466-1. Sci Rep. 2019. PMID: 31727903 Free PMC article.
Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.
Sakurikar N, Eastman A. Sakurikar N, et al. Cell Cycle. 2016 May 2;15(9):1184-8. doi: 10.1080/15384101.2016.1160983. Epub 2016 Mar 17. Cell Cycle. 2016. PMID: 26986210 Free PMC article. Review.
Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays.
Eastman A. Eastman A. Oncotarget. 2017 Jan 31;8(5):8854-8866. doi: 10.18632/oncotarget.12673. Oncotarget. 2017. PMID: 27750219 Free PMC article. Review.
Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.
Warren NJH, Eastman A. Warren NJH, et al. J Biol Chem. 2019 Feb 8;294(6):2192. doi: 10.1074/jbc.RL119.007419. J Biol Chem. 2019. PMID: 30737319 Free PMC article. No abstract available.
Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
Warren NJH, Eastman A. Warren NJH, et al. J Biol Chem. 2019 Feb 8;294(6):1763-1778. doi: 10.1074/jbc.RA118.005231. Epub 2018 Dec 20. J Biol Chem. 2019. PMID: 30573684 Free PMC article.
Will targeting Chk1 have a role in the future of cancer therapy?
Sakurikar N, Eastman A. Sakurikar N, et al. J Clin Oncol. 2015 Mar 20;33(9):1075-7. doi: 10.1200/JCO.2014.60.0767. Epub 2015 Feb 17. J Clin Oncol. 2015. PMID: 25691674 No abstract available.
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.
Thompson R, Eastman A. Thompson R, et al. Br J Clin Pharmacol. 2013 Sep;76(3):358-69. doi: 10.1111/bcp.12139. Br J Clin Pharmacol. 2013. PMID: 23593991 Free PMC article. Review.
Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex.
Garner KM, Pletnev AA, Eastman A. Garner KM, et al. Nat Chem Biol. 2009 Mar;5(3):129-30; author reply 130. doi: 10.1038/nchembio0309-129. Nat Chem Biol. 2009. PMID: 19219009 Free PMC article. No abstract available.
The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition.
Thompson R, Montano R, Eastman A. Thompson R, et al. PLoS One. 2012;7(8):e44021. doi: 10.1371/journal.pone.0044021. Epub 2012 Aug 24. PLoS One. 2012. PMID: 22937147 Free PMC article.
20 results
Jump to page